Context Therapeutics to Participate in Upcoming Investor Conferences
Context Therapeutics (Nasdaq: CNTX) will participate in two investor conferences in November 2025: the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston (Nov 10-12) and the Stifel 2025 Healthcare Conference in New York (Nov 11-13).
At Guggenheim, Context will hold a fireside chat on Nov 10 at 3:00 PM ET plus 1x1 meetings the same day. At Stifel, Context will present on Nov 12 at 10:00 AM ET and hold 1x1 meetings on Nov 12. A live webcast of the presentation will be available on the company website and replays will be posted for 90 days.
For meeting requests, contact your conference representative or IR@contexttherapeutics.com.
Context Therapeutics (Nasdaq: CNTX) parteciperà a due conferenze per investitori nel novembre 2025: la Guggenheim 2nd Annual Healthcare Innovation Conference a Boston (10-12 nov) e la Stifel 2025 Healthcare Conference a New York (11-13 nov).
Alla Guggenheim, Context terrà una conversazione informale il 10 nov alle ore 15:00 ET più incontri 1x1 nello stesso giorno. Alla Stifel, Context presenterà il 12 nov alle 10:00 ET e terrà incontri 1x1 il 12 nov. Una trasmissione in diretta della presentazione sarà disponibile sul sito della società e i replay saranno disponibili per 90 giorni.
Per richieste di incontri, contattare il rappresentante della conferenza o IR@contexttherapeutics.com.
Context Therapeutics (Nasdaq: CNTX) participará en dos conferencias para inversionistas en noviembre de 2025: la Guggenheim 2nd Annual Healthcare Innovation Conference en Boston (del 10 al 12 nov) y la Stifel 2025 Healthcare Conference en Nueva York (del 11 al 13 nov).
En Guggenheim, Context realizará una charla informal el 10 nov a las 3:00 PM ET además de reuniones 1x1 el mismo día. En Stifel, Context presentará el 12 nov a las 10:00 AM ET y llevará a cabo reuniones 1x1 el 12 de noviembre. Una transmisión en vivo de la presentación estará disponible en el sitio web de la empresa y las repeticiones se publicarán por 90 días.
Para solicitudes de reuniones, comuníquese con el representante de la conferencia o IR@contexttherapeutics.com.
Context Therapeutics (나스닥: CNTX) 은 2025년 11월 두 차례의 투자자 컨퍼런스에 참여합니다: Guggenheim 2nd Annual Healthcare Innovation Conference in Boston (11월 10-12일)와 Stifel 2025 Healthcare Conference in New York (11월 11-13일).
Guggenheim에서 Context는 11월 10일 오후 3시 ET에 편안한 대화와 같은 날 1x1 미팅을 가질 예정입니다. Stifel에서는 11월 12일 오전 10시 ET에 발표를 하고 12일에 1x1 미팅을 진행합니다. 발표의 라이브 방송은 회사 웹사이트에서 이용 가능하며 90일 동안 재방송이 게시됩니다.
회의 요청은 컨퍼런스 담당자나 IR@contexttherapeutics.com으로 문의하십시오.
Context Therapeutics (Nasdaq: CNTX) participera à deux conférences d'investisseurs en novembre 2025: la Guggenheim 2nd Annual Healthcare Innovation Conference à Boston (du 10 au 12 nov) et la Stifel 2025 Healthcare Conference à New York (du 11 au 13 nov).
À Guggenheim, Context organisera une conversation en tête-à-tête le 10 nov à 15h00 ET ainsi que des réunions 1x1 le même jour. À Stifel, Context présentera le 12 nov à 10h00 ET et tiendra des réunions 1x1 le 12 nov. Une diffusion en direct de la présentation sera disponible sur le site de l'entreprise et les rediffusions seront publiées pendant 90 jours.
Pour les demandes de rendez-vous, contactez le représentant de la conférence ou IR@contexttherapeutics.com.
Context Therapeutics (Nasdaq: CNTX) wird im November 2025 an zwei Investorenkonferenzen teilnehmen: der Guggenheim 2nd Annual Healthcare Innovation Conference in Boston (10.-12. Nov.) und der Stifel 2025 Healthcare Conference in New York (11.-13. Nov.).
Bei Guggenheim wird Context am 10. Nov. um 15:00 Uhr ET einen Fireside Chat sowie 1x1 Meetings am selben Tag abhalten. Bei Stifel wird Context am 12. Nov. um 10:00 Uhr ET präsentieren und am 12. Nov. 1x1 Meetings durchführen. Eine Live-Übertragung der Präsentation wird auf der Unternehmenswebsite verfügbar sein, und Wiederholungen werden für 90 Tage gepostet.
Für Meeting-Anfragen wenden Sie sich bitte an den Konferenzvertreter oder an IR@contexttherapeutics.com.
Context Therapeutics (ناسداك: CNTX) ستشارك في مؤتمرين للمستثمرين في نوفمبر 2025: Guggenheim 2nd Annual Healthcare Innovation Conference في بوسطن (10-12 نوفمبر) وStifel 2025 Healthcare Conference في نيويورك (11-13 نوفمبر).
في Guggenheim، ستعقد Context محادثة fireside في 10 نوفمبر الساعة 3:00 م بتوقيت ET بالإضافة إلى لقاءات 1x1 في نفس اليوم. في Stifel، ستقدم Context في 12 نوفمبر الساعة 10:00 صباحاً بتوقيت ET وستعقد لقاءات 1x1 في 12 نوفمبر. ستتوفر بث حي للعرض على موقع الشركة وستكون الإعادات متاحة لمدة 90 يوماً.
للطلبات الاجتماعات، يرجى التواصل مع ممثل المؤتمر أو IR@contexttherapeutics.com.
Context Therapeutics (纳斯达克：CNTX) 将在 2025 年 11 月参加两场投资者会议：在波士顿的 Guggenheim 2nd Annual Healthcare Innovation Conference（11 月 10-12 日）以及在纽约的 Stifel 2025 Healthcare Conference（11 月 11-13 日）。
在 Guggenheim，Context 将于 11 月 10 日 3:00 PM ET 举行 炉边对话，并同日进行 1x1 会议。在 Stifel，Context 将于 11 月 12 日 10:00 AM ET 进行演讲并于 12 日举行 1x1 会议。演示的现场网络直播将可在公司网站观看，回放将保留 90 天。
如需安排会面，请联系会议代表或 IR@contexttherapeutics.com。
- None.
- None.
PHILADELPHIA, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its participation in two upcoming investor conferences.
Upcoming Investor Conferences
- Guggenheim 2nd Annual Healthcare Innovation Conference, November 10-12, 2025, Boston
Fireside Chat: Monday, November 10 at 3:00 PM ET*
1x1 Meetings on November 10th
- Stifel 2025 Healthcare Conference, November 11-13, 2025, New York
Presentation: Wednesday, November 12 at 10:00 AM ET
1x1 Meetings on November 12th
*A live webcast of the presentation will be available on the News and Events section of the Company’s website at https://ir.contexttherapeutics.com. Replays will be available on the website for 90 days.
For additional information or to request a meeting with Context’s management team during these events, please contact your conference representative or IR@contexttherapeutics.com.
About Context Therapeutics®
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 TCE, CT-95, a Mesothelin x CD3 TCE, and CT-202, a Nectin-4 x CD3 TCE. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.
Forward-looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the ability of the Company and its employees to participate in and present at conferences, (ii) the potential benefits, characteristics, safety and side effect profile of our product candidates, and (iii) the likelihood data will support future development. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.
Investor Relations Contact:
Jennifer Minai-Azary
Chief Financial Officer
Context Therapeutics
IR@contexttherapeutics.com
FAQ
When will Context Therapeutics (CNTX) present at the Stifel 2025 Healthcare Conference?
What time is Context Therapeutics (CNTX) speaking at the Guggenheim Healthcare Innovation Conference?
Will Context Therapeutics (CNTX) webcast its investor presentation on Nov 12, 2025?
How can investors request a meeting with Context Therapeutics (CNTX) management at the November 2025 conferences?
Which dates will Context Therapeutics (CNTX) attend the Guggenheim and Stifel conferences in 2025?
